Last reviewed · How we verify

NCT05826938

Can Virtual Reality Technology Improve the Patient Experience in Oocyte Retrieval?

Status unknown NA Last updated 28 April 2023
What this trial tests

NA trial testing Virtual reality technology in Infertility, Female in 82 participants. Status unknown.

Timeline
13 March 2023
Primary endpoint
1 March 2024
13 March 2024

Quick facts

Lead sponsorPeter Humaidan
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment82
Start date13 March 2023
Primary completion1 March 2024
Estimated completion13 March 2024
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Peter Humaidan — full company profile →

Who can join

Adults 18 to 40, female only, with Infertility, Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A non-pharmacological, non-blinded, randomized cohort study that will investigate the effect of Virtual Reality technology on the patient experience during oocyte retrieval. The primary objective of the trial is to investigate the impact of Virtual Reality technology on the patient experience

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Virtual reality technology

Trials testing the same drug.

Other recruiting trials for Infertility, Female

Currently open trials in the same condition.

Other Peter Humaidan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05826938.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing